Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
Standard
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. / Jaramillo, S; Benner, A; Krauter, J; Martin, Hans; Kindler, T; Bentz, Martin; Salih, H R; Held, G; Köhne, C-H; Götze, Katharina; Lübbert, M; Kündgen, A; Brossart, P; Wattad, M; Salwender, H; Hertenstein, B; Nachbaur, D; Wulf, G; Horst, H-A; Kirchen, H; Fiedler, W; Raghavachar, A; Russ, Graeme; Kremers, S; Koller, E; Runde, V; Heil, G; Weber, D; Göhring, G; Döhner, K; Ganser, A; Döhner, H; Schlenk, R F.
In: BLOOD CANCER J, Vol. 7, No. 5, 26.05.2017, p. e564.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
AU - Jaramillo, S
AU - Benner, A
AU - Krauter, J
AU - Martin, Hans
AU - Kindler, T
AU - Bentz, Martin
AU - Salih, H R
AU - Held, G
AU - Köhne, C-H
AU - Götze, Katharina
AU - Lübbert, M
AU - Kündgen, A
AU - Brossart, P
AU - Wattad, M
AU - Salwender, H
AU - Hertenstein, B
AU - Nachbaur, D
AU - Wulf, G
AU - Horst, H-A
AU - Kirchen, H
AU - Fiedler, W
AU - Raghavachar, A
AU - Russ, Graeme
AU - Kremers, S
AU - Koller, E
AU - Runde, V
AU - Heil, G
AU - Weber, D
AU - Göhring, G
AU - Döhner, K
AU - Ganser, A
AU - Döhner, H
AU - Schlenk, R F
PY - 2017/5/26
Y1 - 2017/5/26
N2 - The aim of this cohort study was to compare a condensed schedule of consolidation therapy with high-dose cytarabine on days 1, 2 and 3 (HDAC-123) with the HDAC schedule given on days 1, 3 and 5 (HDAC-135) as well as to evaluate the prophylactic use of pegfilgrastim after chemotherapy in younger patients with acute myeloid leukemia in first complete remission. One hundred and seventy-six patients were treated with HDAC-135 and 392 patients with HDAC-123 with prophylactic pegfilgrastim at days 10 and 8, respectively, in the AMLSG 07-04 and the German AML Intergroup protocol. Time from start to chemotherapy until hematologic recovery with white blood cells >1.0 G/l and neutrophils >0.5 G/l was in median 4 days shorter in patients receiving HDAC-123 compared with HDAC-135 (P<0.0001, each), and further reduced by 2 days (P<0.0001) by pegfilgrastim. Rates of infections were reduced by HDAC-123 (P<0.0001) and pegfilgrastim (P=0.002). Days in hospital and platelet transfusions were significantly reduced by HDAC-123 compared with HDAC-135. Survival was neither affected by HDAC-123 versus HDAC-135 nor by pegfilgrastim. In conclusion, consolidation therapy with HDAC-123 leads to faster hematologic recovery and less infections, platelet transfusions as well as days in hospital without affecting survival.
AB - The aim of this cohort study was to compare a condensed schedule of consolidation therapy with high-dose cytarabine on days 1, 2 and 3 (HDAC-123) with the HDAC schedule given on days 1, 3 and 5 (HDAC-135) as well as to evaluate the prophylactic use of pegfilgrastim after chemotherapy in younger patients with acute myeloid leukemia in first complete remission. One hundred and seventy-six patients were treated with HDAC-135 and 392 patients with HDAC-123 with prophylactic pegfilgrastim at days 10 and 8, respectively, in the AMLSG 07-04 and the German AML Intergroup protocol. Time from start to chemotherapy until hematologic recovery with white blood cells >1.0 G/l and neutrophils >0.5 G/l was in median 4 days shorter in patients receiving HDAC-123 compared with HDAC-135 (P<0.0001, each), and further reduced by 2 days (P<0.0001) by pegfilgrastim. Rates of infections were reduced by HDAC-123 (P<0.0001) and pegfilgrastim (P=0.002). Days in hospital and platelet transfusions were significantly reduced by HDAC-123 compared with HDAC-135. Survival was neither affected by HDAC-123 versus HDAC-135 nor by pegfilgrastim. In conclusion, consolidation therapy with HDAC-123 leads to faster hematologic recovery and less infections, platelet transfusions as well as days in hospital without affecting survival.
KW - Journal Article
U2 - 10.1038/bcj.2017.45
DO - 10.1038/bcj.2017.45
M3 - SCORING: Journal article
C2 - 28548643
VL - 7
SP - e564
JO - BLOOD CANCER J
JF - BLOOD CANCER J
SN - 2044-5385
IS - 5
ER -